Theogallin Protects Myocardial Ischemia-Reperfusion Injury by Inhibiting the Interleukin-17 Signaling Pathway

Area of Science:

• Cardiovascular Research
• Pharmacology
• Molecular Biology

Background:

• Tea polyphenols exhibit cardioprotective effects via antioxidant and anti-inflammatory actions.
• Theogallin, a unique tea-derived polyphenol, has an unclear role in preventing myocardial ischemia-reperfusion (I/R) injury.
• Understanding theogallin's mechanism is crucial for developing novel therapeutic strategies for heart conditions.

Purpose of the Study:

• To investigate the cardioprotective effects of theogallin against myocardial I/R injury.
• To elucidate the underlying molecular mechanisms, particularly the involvement of the IL-17 signaling pathway.
• To evaluate theogallin's efficacy in both ex vivo and in vivo models of cardiac injury.

Main Methods:

• Utilized an ex vivo Langendorff perfusion model of I/R injury in isolated rat hearts.
• Employed an in vivo myocardial injury model using left anterior descending coronary artery (LAD) ligation in rats.
• Assessed hemodynamic parameters, myocardial enzyme release, infarct size, fibrosis, and gene expression related to the IL-17 pathway.

Main Results:

• Theogallin pretreatment significantly improved hemodynamic function in isolated hearts subjected to I/R.
• In vivo, theogallin administration enhanced myocardial contractile function and reduced cardiac enzyme release.
• Theogallin significantly decreased infarct size and cardiac fibrosis, while downregulating key IL-17 pathway components (IL-17RA, JUNB, FRA1, MMP9).

Conclusions:

• Theogallin demonstrates significant cardioprotective effects against myocardial I/R injury in rat models.
• These protective effects are mediated by the inhibition of the IL-17 signaling pathway.
• Theogallin represents a potential therapeutic agent for managing myocardial I/R injury.